(Society of Nuclear Medicine) Two new studies published in the August issue of The Journal of Nuclear Medicine (JNM) provide insight into the potential of positron emission tomography (PET) to differentiate between types of dementia and to identify pharmaceuticals to slow the progress of dementia. With proposed National Institute on ...

GTx, Inc. (Nasdaq: GTXI) announced today that the effects of Ostarine™ (GTx-024) on physical function in patients with non-small cell lung cancer (NSCLC) will be the subject of an oral podium presentation at the 14th Annual World Conference on Lung Cancer, the annual meeting of the International Association for the ...

Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, announces that data from its Phase 2 PV-10 metastatic melanoma study will be presented at two upcoming melanoma conferences. On June 21, 2011, Dr. Sanjiv Agarwala, Chief of Medical Oncology and Hematology at St. Luke's Hospital ...

Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced that the results of clinical studies using Uroplasty's Urgent PC Neuromodulation System and Macroplastique urethral bulking agent products are scheduled to be presented at three upcoming professional meetings.

Anacor Pharmaceuticals announced today that it will present data on two of its compounds at the following conferences: “Safety and efficacy of AN2728 ointment in a phase 2b dose-ranging bilateral study of mild-to-moderate plaque psoriasis”.

Neuralstem, Inc. (NYSE Amex: CUR) announced that the Phase I safety trial of its human spinal cord stem cells (HSSCs) in amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) is the subject of three presentations at the American Academy of Neurology (AAN) Annual Meeting, April 9-16th, in Honolulu, HI (click ...

ROCKVILLE, April 6, Maryland, 2011 Neuralstem, Inc. (NYSE Amex: CUR) announced that the Phase I safety trial of its human spinal cord stem cells (HSSCs) in amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) is the subject of three presentations at the American Academy of Neurology (AAN) Annual Meeting, ...

(Neuralstem, Inc.) Neuralstem's Phase I stem cell trial in ALS (Lou Gehrig's disease) is to be the subject of multiple presentations at the American Association of Neurologists conference. Interim results will be presented.

Guided Therapeutics, Inc. (OTCBB & OTCQB: GTHP) announced that its non-invasive and painless test for the early detection of cervical precancer, the LightTouch™, will be the subject of a presentation at The American College of Obstetricians and Gynecologists (ACOG) 59th Annual Clinical Meeting to be held April 30 - May ...

Guided Therapeutics, Inc. (OTCBB & OTCQB: GTHP) announced that its non-invasive and painless test for the early detection of cervical precancer, the LightTouch™, will be the subject of a presentation at The American College of Obstetricians and Gynecologists (ACOG) 59th Annual Clinical Meeting to be held April 30 - May ...

At least one dengue vaccine could be licensed within the next 4 years, as manufacturers are speeding up the development process for multiple dengue vaccine candidates in collaboration with health authorities and developing countries to expedite the necessary testing, clinical trial design, and licensure, a team of leading scientists said.

TIME reports on an oral cholera vaccination program to kick off on Thursday in Bangladesh that researchers hope will determine how good of a "weapon" the mass vaccination strategy can be "against an old disease".